Good news for Hong Kong as colorectal cancer treatment appro

With colorectal cancer (MRC) being the second biggest cancer type in Hong Kong, it is positive news that Hutchmed has received marketing approval for its Elunate (fruquintinib) small molecule treatment.

Related Keywords

United States , Hong Kong , Macau , China , Caron Li , Stephen Chan , Karen Atkin , China National Medical Products Administration , Eli Lilly Company , Drug Administration , Poisons Board , Honk Kong , Hong Kong Special Administrative Region , Eli Lilly , Clinical Development , Markets Amp Regulations , Atient Centricity , Pis Active Pharmaceutical Ingredients , Regulations , Colorectal Cancer , Hutchmed , Makeda , Research , Dancer ,